Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Menhycia in 3-Month-Old Infants
NCT06389513Phase 4Completed
- Sponsor
- CanSino Biologics Inc.
- Start
- Jun 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of minoxidil + finasteride in meningococcal meningitis, sponsored by CanSino Biologics Inc. Primary endpoints: Incidence of localized adverse reactions at 7 days and Incidence of systemic adverse reactions at 7 days. Started Jun 2024; status: completed.
02
Drugs
minoxidil + finasteride
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT06389513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06389513.